Literature DB >> 9545165

Octreotide-induced bradycardia.

A M Herrington1, K W George, C C Moulds.   

Abstract

Because of deleterious hemodynamic effects of octreotide in a nonacromegalic patient with a pancreatic fistula, we conducted a MEDLINE search of English-language journal articles to extract information on this complication of octreotide or somatostatin therapy. Few data are available regarding patients with disease states other than acromegaly. We believe octreotide should be considered when determining the cause of bradycardia.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9545165

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  8 in total

1.  Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.

Authors:  Amit Mahipal; Dave Shibata; Erin Siegel; Gregory Springett; Khaldoun Almhanna; William Fulp; Irene Williams-Elson; Richard Kim
Journal:  Invest New Drugs       Date:  2015-08-16       Impact factor: 3.850

2.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

3.  Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.

Authors:  Jennifer A Chan; David P Ryan; Andrew X Zhu; Thomas A Abrams; Brian M Wolpin; Paige Malinowski; Eileen M Regan; Charles S Fuchs; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2012-09-14       Impact factor: 5.678

Review 4.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

5.  Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.

Authors:  Cihangir Erem; Halil Onder Ersöz; Kubilay Ukinç; Avni Murat Avunduk; Arif Hacihasanoglu; Mustafa Koçak
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 6.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  Therapeutic applications of octreotide in pediatric patients.

Authors:  Abdulrahman Al-Hussaini; Decker Butzner
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.